11 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 18 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 11, Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Synovitis: new trials by email Literature Review of Synovitis trials Research Report on Synovitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 84 | 2027-10-01 | 2026-07-16 |
| A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT DCC-3014 - Tenosynovial Giant Cell Tumor | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 18 | 2026-10-31 | 2026-09-22 |
| Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) Pimicotinib - Tenosynovial Giant Cell Tumor | Phase 2 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 20 | 2026-03-26 | 2026-10-23 |
| Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA Methotrexate (MTX), Placebo - Osteo Arthritis of the Knee, Synovitis of Knee | Phase 2 | Recruiting | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 70 | 2025-07-30 | 2025-09-12 |
| A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT AMB-05X - Pigmented Villonodular Synovitis, TGCT | Phase 2 | Completed | AmMax Bio, Inc. | 20 | 2023-01-26 | 2024-07-05 |
| A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 2 | Terminated | AmMax Bio, Inc. | 4 | 2021-09-16 | 2024-05-24 |
| An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS) | Phase 2 | Completed | AmMax Bio, Inc. | 11 | 2021-05-25 | 2024-06-27 |
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 2 | Completed | Daiichi Sankyo Co., Ltd. | 9 | 2021-03-15 | 2026-06-24 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1 / Phase 2 | Completed | Five Prime Therapeutics, Inc. | 66 | 2015-06-01 | 2021-08-31 |
| A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis ABT-981, Placebo - Knee Osteoarthritis, Medial Compartment Knee Osteoarthritis | Phase 2 | Completed | AbbVie | 350 | 2014-06-04 | 2019-08-28 |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) MCS110, Placebo - Pigmented Villonodular Synovitis, PVNS | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2012-04-23 | 2021-01-05 |
| The Use of PET/CT to Evaluate Synovitis in the Temporomandibular Joint (TMJ) PET/CT with 18-FDG - Temporomandibular Joint, Conservative Treatment Therapy | Phase 2 | Withdrawn | University of Pennsylvania | 2011-12-01 | 2015-07-08 | |
| Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Tasigna - Pigmented Villonodular Synovitis | Phase 2 | Completed | Centre Leon Berard | 50 | 2010-12-01 | 2013-04-16 |
| Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements Placebo, Apatone®B - Edematous, Synovitis | Phase 2 | Completed | IC-MedTech Corporation | 57 | 2010-10-01 | 2018-01-31 |
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor nilotinib - Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | Phase 2 | Completed | Andrew J. Wagner, MD, PhD | 17 | 2010-09-01 | 2026-11-10 |
| Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis etanercept, placebo - Persistent Knee Joint Synovitis | Phase 2 | Completed | University of Padova | 31 | 2005-04-01 | 2008-05-16 |
| Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy Methotrexate, Fludarabine - Arthritis, Rheumatoid, Synovitis | Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 40 | 1998-06-01 | 2008-03-04 |
Giant Cell Tumor of Tendon Sheath (10) · Synovitis, Pigmented Villonodular (10) · Arthritis, Rheumatoid (2) · Arthritis (1) · Arthritis, Psoriatic (1) · Edema (1) · Facial Pain (1) · Foreign-Body Reaction (1) · Osteoarthritis (1) · Osteoarthritis, Knee (1) · Osteolysis (1) · Pain (1) · Spondylarthropathies (1)
Joint Diseases (18) · Musculoskeletal Diseases (18) · Giant Cell Tumors (12) · Muscular Diseases (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Connective Tissue (12) · Neoplasms, Connective and Soft Tissue (12) · Tendinopathy (12) · Pathological Conditions, Signs and Symptoms (3) · Rheumatic Diseases (3) · Signs and Symptoms (3) · Arthritis (2) · Autoimmune Diseases (2)
Methotrexate (2) · nilotinib (2) · Etanercept (1) · Fluorodeoxyglucose F18 (1) · cabiralizumab (1) · fludarabine (1) · lutikizumab (1) · pexidartinib (1)
AmMax Bio, Inc. (3) · AbbVie (1) · Andrew J. Wagner, MD, PhD (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Centre Leon Berard (1) · Daiichi Sankyo Co., Ltd. (1) · Deciphera Pharmaceuticals, LLC (1) · Five Prime Therapeutics, Inc. (1) · IC-MedTech Corporation (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Novartis Pharmaceuticals (1) · Ono Pharmaceutical Co., Ltd. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Padova (1)
United States (9) · Netherlands (5) · Poland (5) · France (3) · Italy (3) · Japan (3) · United Kingdom (3) · Australia (2) · Ukraine (2) · Bangladesh (1) · Canada (1) · China (1) · Hungary (1) · South Korea (1) · Spain (1)
Dorothy Nguyen, MD (3) · Andrew J. Wagner, MD, PhD (1) · Jean Yves Blay, PR (1) · Maitreyi Sharma, MD (1) · Marc Levesque, MD (1) · Mark W Kovacik, BS (1) · Project Leader (1) · Shamim Ahmed Professor, FCPS (1) · Thomas F Bear, MD (1) · Ugo Fiocco, MD, PhD (1)
PMID 22751595, PMID 22867975, PMID 29571946, PMID 30653843, PMID 35932628